The market size of In-Vitro diagnostics in the Asia Pacific region has been estimated at USD 13.31 billion in 2019 and is poised to reach 18.15 billion in 2024 at a Compound Annual Growth Rate (CAGR) of 6.4%. Increasing population especially elderly people across the Asia Pacific region is a key driving factor for the market to grow.
In the Asia Pacific, there is a quiet increment in the scale of a number of diagnostics centers and hospitals which is straightly propelling the demand of the in-vitro diagnostics market. In-vitro diagnostics are very popular in giving accurate results in very little time where this is attracting many of the consumers. This attribute is expanding the size of the market to the extent. In addition, rising incidences of cancer and diabetes among many individuals is fuelling the growth rate of the market.
However, the cost of installation and maintenance of some equipment in laboratories is a bit expensive which is declining the growth rate of the market. Fluctuations in the prices of various raw materials required to manufacture the devices are also restraining the demand of the Asia Pacific in-vitro diagnostics market. Government authorities are very strict in approving new IVD products in concern towards people’s safety is remained as a challenging thing for the market developers. Lack of professionals in monitoring the systems is hampering the growth rate of the market in the Asia Pacific.
Increasing research on the development of new products with the latest technologies is creating chances for the market to grow. Rise in the investments from both public and private organizations to improve services in diagnostics centers is likely to outshine the demand of the market. Besides, growing demand for early diagnosis in most of the countries is leveling up the growth rate of the Asia Pacific in-vitro diagnostics market. Diagnosis of a disease is prior to having a proper and efficient treatment procedure and this greatly influencing the demand of the market eventually. Furthermore, escalating expenditure on healthcare in developed and developing countries is ascribed to bolster the growth rate of the market in this region.
This research report segmented and sub-segmented into the following categories:
By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC
On the basis of geography, China Is the largest market for In-Vitro diagnostics accounting for a share of around XX% owing to the growing prevalence of chronic diseases such as cancer and respiratory diseases in the region while India is estimated to be the fastest-growing segment with a CAGR of XX%.
Noteworthy companies operating in the APAC IVD Market are Abbott Laboratories, Johnson and Johnson, Siemens Healthcare, Becton Dickinson, Roche Diagnostic, Beckman Coulter Inc., Biomérieux, Ortho Clinical Diagnostics, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Sysmex Corporation and Thermo Fisher Scientific, Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Product
5.1.1 Instruments
5.1.2 Reagents and Kits
5.1.3 Software
5.2 By Technology
5.2.1 Clinical Chemistry
5.2.2 Hematology
5.2.3 Immunoassays
5.2.4 Coagulation and Hemostasis
5.2.5 Molecular Diagnostics
5.2.6 Microbiology
5.2.7 Other IVD technologies
5.3 By Application
5.3.1 Diabetes
5.3.2 Infectious Diseases
5.3.3 Oncology/Cancer
5.3.4 Cardiology
5.3.5 Nephrology
5.3.6 Autoimmune Diseases
5.3.7 Drug Testing
5.3.8 HIV
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Johnson and Johnson
8.3 Siemens Healthcare
8.4 Becton Dickinson
8.5 Roche Diagnostics
8.6 Beckman Coulter Inc.
8.7 Biomérieux
8.8 Ortho Clinical Diagnostics, Inc.
8.9 Bio-Rad Laboratories, Inc.
8.10 Danaher Corporation
8.11 Sysmex Corporation
8.12 Thermo Fisher Scientific, Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
Aug 2019
Download Sample
